# Vaginal oestrogen after breast cancer: what the evidence says, and where it disagrees

Source: https://onco.cc/technologies/vaginal-oestrogen-after-breast-cancer/  
OnCo record `vaginal-oestrogen-after-breast-cancer` (Technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Vaginal dryness and painful sex after cancer treatment are common, lasting and under-treated. Low-dose vaginal oestrogen is the usual answer outside cancer, and for women on an aromatase inhibitor the guidance disagrees: American and British bodies read the same cohort studies differently. A reader deserves to be told that rather than given one confident answer.

## Summary

Moisturisers and lubricants are first line everywhere, and all the major guidelines say so. The question is what to do when they are not enough.

What is known about absorption. In seven postmenopausal women on aromatase inhibitors, a vaginal oestradiol tablet raised serum oestradiol from 5 picomoles per litre or less to a mean of 72 at two weeks, falling below 35 in most by four weeks; the authors titled the paper a caution and concluded it "is contraindicated". Seven women is a very small basis for a widely quoted conclusion. A randomised placebo-controlled trial of ultra-low-dose 0.005 per cent estriol gel in 61 women on a non-steroidal aromatase inhibitor found it "did not significantly influence estrogens, FSH, and LH levels".

What is known about recurrence. A Danish cohort of 8,461 women found an adjusted relative risk of recurrence with vaginal oestrogen of 1.08 (0.89 to 1.32) overall, but 1.39 (1.04 to 1.85) in the subgroup also taking an aromatase inhibitor, with lower overall mortality in users. A Scottish and Welsh cohort of 49,237 women found no higher breast cancer mortality in users (hazard ratio 0.77, 0.63 to 0.94), but measured mortality rather than recurrence and did not report an aromatase-inhibitor subgroup. A United States claims analysis of 10,584 women with oestrogen-receptor-positive disease found recurrence risk ratio 0.94 (0.77 to 1.15). A 2025 meta-analysis of six observational studies covering 38,050 women on endocrine therapy concluded that in those on an aromatase inhibitor, topical oestrogen "did not increase all-cause mortality" but "may convey an increased risk of recurrence" (relative risk 2.51, 1.10 to 5.72), rated low certainty, and that such a risk "cannot be ruled out".

Where the guidance parts. The American College of Obstetricians and Gynecologists wrote in 2016 that "data do not show an increased risk of cancer recurrence among women currently undergoing treatment for breast cancer or those with a personal history of breast cancer who use vaginal estrogen", with vaginal oestrogen "reserved for those patients who are unresponsive to nonhormonal remedies"; that opinion predates the Danish and British cohorts. The Menopause Society in 2020 said "there are insufficient data at present to confirm the safety of vaginal estrogen or DHEA or ospemifene in women with breast cancer". The British Menopause Society in 2025 is the sharpest: "Neither systemic HRT nor low-dose vaginal estrogen are recommended in women taking an aromatase inhibitor", while "vaginal estrogen can be used in women taking tamoxifen but generally not aromatase inhibitors". ASCO's 2018 guideline keeps it open: lubricants and moisturisers first, and "low-dose vaginal estrogen, lidocaine, and dehydroepiandrosterone may also be considered in some cases".

The non-hormonal alternatives are weaker than their reputation. In a three-arm randomised trial in postmenopausal women, neither a low-dose vaginal oestradiol tablet nor an over-the-counter moisturiser beat placebo gel. Vaginal dehydroepiandrosterone in 464 cancer survivors missed its primary endpoint against plain moisturiser at 12 weeks, though sexual function scores improved. Fractional carbon dioxide laser was no better than sham in a 12-month randomised trial, and it is not funded for this outside research in the United Kingdom.

What comes back, and when: without treatment, it does not. Genitourinary symptoms after an abrupt menopause persist and usually worsen, which is the reason to treat rather than wait. Every option above is a treatment to be continued, not a cure.

## Fields

- Kind: Technology
- Status: established
- Last checked: 2026-10-02
- Tags: rejuvenation; survivorship; evidence:moderate
- Principle: Oestrogen maintains vaginal epithelial thickness, glycogen content and the lactobacillus-dominant acidic environment. Withdrawal thins the epithelium and raises pH, producing dryness, fragility, pain and urinary symptoms. A low-dose vaginal preparation aims to restore local tissue without meaningful systemic exposure; in women whose treatment depends on near-complete oestrogen suppression, whether that aim is achieved is the entire question.
- Strengths: Large cohorts, several of them national, rather than case series; The disagreement between guidelines is explicit and can be shown to the reader; Non-hormonal first-line options are safe and available without a prescription
- Limitations: No randomised trial of recurrence risk exists and none is likely; The aromatase-inhibitor signal is from subgroup and pooled observational analyses rated low certainty; Moisturiser, vaginal DHEA and laser each failed to beat a control in their best trial

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Genitourinary_syndrome_of_menopause
- Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors (Ann Oncol 2006): https://doi.org/10.1093/annonc/mdj127
- Systemic or vaginal hormone therapy after early breast cancer: a Danish observational cohort study (JNCI 2022): https://doi.org/10.1093/jnci/djac112
- Vaginal estrogen therapy use and survival in females with breast cancer (JAMA Oncol 2024): https://doi.org/10.1001/jamaoncol.2023.4508
- Safety of topical estrogen therapy during adjuvant endocrine treatment: meta-analysis and expert panel discussion (Cancer Treat Rev 2025): https://doi.org/10.1016/j.ctrv.2025.102880
- The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society (Menopause 2020): https://doi.org/10.1097/GME.0000000000001609
- Efficacy of vaginal estradiol or vaginal moisturizer versus placebo for postmenopausal vulvovaginal symptoms (JAMA Intern Med 2018): https://doi.org/10.1001/jamainternmed.2018.0116
- Vaginal dehydroepiandrosterone for vaginal symptoms in postmenopausal cancer survivors (NCCTG N10C1) (Support Care Cancer 2018): https://doi.org/10.1007/s00520-017-3878-2
- Fractional carbon dioxide laser versus sham for postmenopausal vaginal symptoms (JAMA 2021): https://doi.org/10.1001/jama.2021.14892
- ACOG Committee Opinion 659: the use of vaginal estrogen in women with a history of estrogen-dependent breast cancer: https://doi.org/10.1097/AOG.0000000000001351
- British Menopause Society consensus statement: the benefits and risks of HRT before and after a breast cancer diagnosis: https://thebms.org.uk/publications/consensus-statements/

## Connected records

- ideas: [Sexual health assessed and treated as a standard toxicity domain](https://onco.cc/ideas/idea-moon-sexual-health-as-toxicity-domain/)
- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/), [Endometrial cancer](https://onco.cc/cancers/endometrial/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- fronts: [Hormonal Therapy](https://onco.cc/fronts/hormonal/), [Recovery & Rejuvenation](https://onco.cc/fronts/rejuvenation/), [Supportive Care & Survivorship](https://onco.cc/fronts/supportive-care/)
- technologies: [Endocrine therapy (SERMs, AIs, SERDs)](https://onco.cc/technologies/endocrine-therapy/), [Menopause brought on by cancer treatment, and the options for it](https://onco.cc/technologies/menopause-after-cancer-treatment/), [Sexual function and intimacy after cancer, for both sexes](https://onco.cc/technologies/sexual-function-after-cancer/), [Survivorship care and late-effects surveillance](https://onco.cc/technologies/survivorship-care-plan/)
- drugs: [Anastrozole](https://onco.cc/drugs/anastrozole/), [Exemestane](https://onco.cc/drugs/exemestane/), [Letrozole (and other aromatase inhibitors)](https://onco.cc/drugs/letrozole/), [Tamoxifen](https://onco.cc/drugs/tamoxifen/)
- terms: [Aromatase inhibitor](https://onco.cc/terms/aromatase-inhibitor/), [Late effects and survivorship toxicity](https://onco.cc/terms/late-effects/), [Menopause symptoms after chemotherapy for breast cancer](https://onco.cc/terms/menopause-after-chemotherapy-breast/)
- bottlenecks: [Survivorship and late effects are neglected](https://onco.cc/bottlenecks/b-survivorship/), [Toxicity and quality of life are undervalued](https://onco.cc/bottlenecks/b-toxicity-qol/)

---
JSON: https://onco.cc/api/v1/entities/vaginal-oestrogen-after-breast-cancer.json